SPRB

Spruce Biosciences, Inc. Common Stock

SPRB

Market cap $5.36M

Overview Fund Activity

9.52 USD

0.00

0%

1 day

0%

5 days

-13.45%

1 month

-2.86%

3 months

-2.86%

6 months

-61.03%

Year to date

-69.74%

1 year

-71.64%

5 years

-99.25%

10 years

-99.25%

About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.

Employees: 20

Healthcare Drug Manufacturers - General

–

Funds holding %

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

90% less funds holding

Funds holding: 30 [Q1] → 3 (-27) [Q2]

95% less capital invested

Capital invested by funds: $3.02M [Q1] → $147K (-$2.88M) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 27

See Fund Rankings

Financial journalist opinion

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol “SPRB” and CUSIP 85209E 208. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company.

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2025 and provided corporate updates. “We remain steadfast in our efforts to advance TA-ERT as a potential first-to-market treatment for children diagnosed with Sanfilippo Syndrome T.

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced results from a long-term data integration of tralesinidase alfa enzyme replacement therapy (TA-ERT) clinical program in patients with Sanfilippo Syndrome Type B (MPS IIIB). Spruce integrated and evaluated group-level efficacy data for c.

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it will implement a 1-for-75 reverse stock split of its issued and outstanding shares of common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on August 4, 2025. The Reverse Stock Split was approved by the compa.

Spruce Biosciences Announces Reverse Stock Split

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that the first patient has been dosed in the Phase 2 clinical trial called “Tildacerfont as Antidepressant Medication and Relief in Depression” (TAMARIND).

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC (“Nasdaq”) to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or bef.

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients a.

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences Investor Call [Operator Instructions].

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). “This is truly a transformative moment for Spruce as we focus ou.

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Zacks Investment Research

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

See News Rankings

Charts implemented using Lightweight Charts™